high-risk smoldering multiple myeloma | International Myeloma Foundation

IMF conference series

Week in Review

July 16

Top Takeaways from The IMF Conference Series: Highlights from ASCO, IMWG, and EHA 2026

Patient being assured by doctor

Week in Review

February 5

Frequently Asked Questions (FAQ): The Updated ASCO Living Guideline for Multiple Myeloma

Dr. Shaji Kumar on working with the IMF

November 29

Can We Prevent Multiple Myeloma? | Dr. Shaji Kumar on Risk, MGUS, Early Treatment

2025 IMWG Summit

Week in Review

November 13

Top Takeaways from the 2025 IMWG, ASCO, and EHA Annual Meetings

PFS-LA fireside chat with Dr. Kumar

Week in Review

September 18

2025 Patient and Family Seminar Los Angeles: Highlights of the Fireside Chat on the Future of Myeloma

ODAC vote

Week in Review

June 5

A Closer Look at the FDA ODAC Vote Recommending DARZALEX FASPRO® as Treatment for High-Risk Smoldering Myeloma

telehealth communication

Week in Review

May 29

April and May 2025: What's New in Myeloma? 

Primary Results of the Aquila Study

February 24

Daratumumab vs Active Monitoring in High-Risk Smoldering Multiple Myeloma: Aquila Study Results

New Standard of Care for High-Risk Smoldering Multiple Myeloma

January 23

New Standard of Care for High-Risk Smoldering Multiple Myeloma: Insights from ASH 2024

What is high-risk smoldering multiple myeloma?

November 16

What is high-risk smoldering multiple myeloma?

scientists in research lab

Week in Review

February 9

Myeloma News: From Iceland to China

Dr Shaji Kumar ASH abstract on the ASCENT trial

February 3

Fixed Duration Therapy with Dara-KRd for High Risk Smoldering Multiple Myeloma: ASCENT Trial

Subscribe to high-risk smoldering multiple myeloma

Give Where Most Needed